Equity · Healthcare
Johnson & Johnson (JNJ) perpetual futures
JNJ perpetual futures on 11 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade JNJUSDT.
Johnson & Johnson is a healthcare holding company operating in Innovative Medicine and MedTech segments, developing and selling pharmaceuticals and medical devices.
Price chart
Use the left and right arrow keys to inspect points on the chart.
Trading data
Perpetual market activity
11/11 live markets
Trading data
Perpetual market activity
Spot performance
Venue matrix
11 markets
Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.
| Trade | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bybit | Trade | JNJ/USDT | Trading | $266.03 | 0.0% APR 0.000% every 8h | +0.8 bps | $18.5K | $363.5K | $490.7K | USDT | 25x | |
BingX | Trade | JNJ-USDT | Trading | $266.52 | +5.5% APR +0.00500% every 8h | +16.9 bps | $105.8K | $176.1K | $2.6K | USDT | - | |
Bitget | Trade | JNJ/USDT | Trading | $266.75 | 0.0% APR 0.000% every 8h | +8.3 bps | $262K | $162.8K | $238.2K | USDT | 20x | |
Binance | Trade | JNJ/USDT | Trading | $266.34 | 0.0% APR 0.000% every 8h | +12.4 bps | $20.4K | $132.5K | $54.5K | USDT | - | |
MEXC | Trade | JNJ/USDT | Trading | $267.83 | 0.0% APR 0.000% every 8h | +44.6 bps | $11.5K | $101.9K | $24.1K | USDT | 20x | |
XT.com | Trade | JNJ/USDT | Trading | $266.03 | 0.0% APR 0.000% every 8h | +5.6 bps | $40.4K | $61.1K | - | USDT | 20x | |
OKX | Trade | JNJ/USDT | Trading | $266.09 | 0.0% APR 0.000% every 8h | +4.9 bps | $15.1K | $43.9K | $145.2K | USDT | 10x | |
HTX | Trade | JNJ/USDT | Trading | $266.72 | +11.0% APR +0.010% every 8h | +142.5 bps | $87.2K | $31.4K | $5.5K | USDT | - | |
Bitunix | Trade | JNJ/USDT | Trading | $266.42 | -2.6% APR -0.00236% every 8h | +14.6 bps | $50.7K | $6.9K | $1.1K | USDT | 20x | |
Gate.io | Trade | JNJ/USDT | Trading | $266.33 | 0.0% APR 0.000% every 8h | +33.1 bps | $7.5K | $2.6K | $178.3K | USDT | 20x | |
LBank | Trade | JNJ/USDT | Trading | $266.47 | 0.0% APR 0.000% every 8h | +14.3 bps | $4.6M | $683.9K⚠ | $204.9 | USDT | 50x |
Unverified volume: implausibly high against open interest, a typical sign of wash trading. These venues are listed last.
Tokenized wrappers of the real stock, tradable on-chain and on crypto exchanges around the clock. Premium/discount compares the token price to our stock reference price. Data: CoinMarketCap · Robinhood · DexScreener · GeckoTerminal.
| Product | Price | Premium vs stock | 24h Vol. | Market Cap | Chains |
|---|---|---|---|---|---|
| JNJXxStocks | $265.87 | -0.23% | $2k | $593k | Solana · Arbitrum · BNB Smart Chain (BEP20) · Ethereum |
| WJNJXxStocks | $270.95 | +1.68% | $1k | $4k | X Layer · Arbitrum |
| JNJRobinhood | $270.87 | +1.65% | $51 | $188k | Robinhood Chain |
| Exchange | Pair | Price | 24h Vol. | Liquidity |
|---|---|---|---|---|
ramsesDEX · robinhood | JNJ/USDG ↗ | $270.87 | $51 | $17k |
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100k
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100kBroad liquidity · 8 of 11 venues absorb $10k · Typical cost: +27.7 bps – +60.1 bps
Cheapest execution: LBank · +13.3 bps
Too thin: OKX, Gate.io
No fresh book data: HTX
Taker execution estimate incl. approx. fees - maker fills are not guaranteed.
Best venues for this underlying
Best liquidity
JNJTightest spread
JNJHighest volume
JNJFunding history
Stored venue snapshots by market
Funding history
Stored venue snapshots by marketNext catalyst
Catalysts
Next catalyst
Catalysts
No unusual perp activity right now.
Research data
Analysts, filings and peer context
Research data
Analysts, filings and peer context
Estimates
6Company events
6Peer comparison
Similar listed perpsRevenue mix
Latest annualAnalysts
Price targets in USD| Consensus rating | Buy |
|---|---|
| Average 12-month price target | $285.31 |
| 12-month target range (low – high) | $260 – $320 |
| Ratings in the provider's consensus | 40 |
Price targets as of 2026-11-21
Analyst rating history
Ratings| Month | Strong buy | Buy | Hold | Sell | Strong sell |
|---|---|---|---|---|---|
| Nov 2026 | 5 | 11 | 6 | 2 | 0 |
| Oct 2026 | 5 | 11 | 6 | 1 | 0 |
| Sep 2026 | 5 | 11 | 6 | 1 | 0 |
| Aug 2026 | 5 | 11 | 6 | 1 | 0 |
| Jul 2026 | 5 | 11 | 7 | 1 | 0 |
| Jun 2026 | 5 | 10 | 8 | 1 | 1 |
| May 2026 | 5 | 10 | 10 | 0 | 1 |
| Apr 2026 | 5 | 9 | 10 | 1 | 1 |
| Mar 2026 | 5 | 9 | 10 | 0 | 1 |
| Feb 2026 | 5 | 9 | 10 | 0 | 1 |
| Jan 2026 | 5 | 9 | 11 | 0 | 1 |
| Dec 2025 | 4 | 9 | 11 | 0 | 1 |
Ownership
Institutional · 2026-Q2Reference market activity
JNJ-PERPPrice performance
11Insider activity
FY2026 Q4Insider transactions
25J&J officer Forminard Elizabeth exercised 13,072 employee stock options at $151.41 and sold the same 13,072 common shares at $284.39 on 2026-11-12, leaving 16,994 shares owned.
Director Pinto Daniel E received a 113-share award of Deferred Share Units in Johnson & Johnson, holding 2,445 units after. This is an A-Award grant, not a purchase.
Johnson & Johnson director Eugene A. Woods received a 136-share award of Deferred Share Units on 2026-09-08, an A-Award grant at $0.00, bringing his holdings to 6,579 units.
Johnson & Johnson director Marillyn A. Hewson was granted 181 deferred share units at $0.00 on Sept 8, 2026, bringing her holding to 16,049 units.
JNJ officer Timothy Schmid exercised 33,597 employee stock options (M-Exempt) at $131.94-$151.41 and sold 22,527 common shares on the open market at $274.74.
J&J officer Thomas Cavanaugh filed an initial Form 3 disclosing holdings: 7 employee stock option grants (strike $151.41–$243.45), 3 restricted share unit awards and 2 common stock entries, all reported with 0 shares transacted.
J&J officer Taubert exercised options on 15,000 common shares at $115.67 and sold 15,000 shares at $263.36 on 2026-08-17, leaving 194,451 shares owned.
Filings
51 · Latest SEC filingsJ&J officer Forminard Elizabeth exercised 13,072 employee stock options at $151.41 and sold the same 13,072 common shares at $284.39 on 2026-11-12, leaving 16,994 shares owned.
Director Pinto Daniel E received a 113-share award of Deferred Share Units in Johnson & Johnson, holding 2,445 units after. This is an A-Award grant, not a purchase.
Johnson & Johnson director Eugene A. Woods received a 136-share award of Deferred Share Units on 2026-09-08, an A-Award grant at $0.00, bringing his holdings to 6,579 units.
Johnson & Johnson director Marillyn A. Hewson was granted 181 deferred share units at $0.00 on Sept 8, 2026, bringing her holding to 16,049 units.
JNJ officer Timothy Schmid exercised 33,597 employee stock options (M-Exempt) at $131.94-$151.41 and sold 22,527 common shares on the open market at $274.74.
J&J officer Thomas Cavanaugh filed an initial Form 3 disclosing holdings: 7 employee stock option grants (strike $151.41–$243.45), 3 restricted share unit awards and 2 common stock entries, all reported with 0 shares transacted.
J&J officer Taubert exercised options on 15,000 common shares at $115.67 and sold 15,000 shares at $263.36 on 2026-08-17, leaving 194,451 shares owned.
CEO Joaquin Duato exercised 123,291 stock options at $115.67 and sold the same 123,291 shares on 2026-08-13 in two sales at $261-$262, leaving 275,967 shares directly owned.
CEO Joaquin Duato sold 48,480 common shares of Johnson & Johnson in two open-market transactions on August 5, 2026, at prices between $258.056 and $258.739 per share.
JNJ officer Elizabeth Forminard exercised 9,344 options at $131.94 (converting them into 9,344 common shares) and sold 15,918 common shares at $255.932-$257.755 across two open-market sales; she retained 16,994 shares.
Johnson & Johnson officer Vanessa Broadhurst exercised employee stock options on 23,054 common shares at $129.51-$131.94, then sold all 23,054 shares at $251.266 (Form 4, filed 2026-07-21).
Kathryn Wengel exercised options on 10,000 JNJ shares at $115.67 and then sold all 10,000 shares at $241.15.
Director Marillyn A. Hewson was awarded 215 Deferred Share Units as compensation, bringing her total holdings to 15,792 units.
Director Eugene A. Woods was awarded 161 Deferred Share Units as compensation on 2026-06-09, bringing his total holdings to 6,412 units.
Director Daniel E. Pinto received a grant of 134 Deferred Share Units in Johnson & Johnson, bringing his total holding to 2,321 units. This was a compensation award, not an open-market purchase.
Johnson & Johnson officer John C. Reed exercised 25,255 restricted share units into 25,255 common shares, then 11,002 shares were withheld at $229.85 to cover tax, leaving 24,911 shares owned.
Director Jennifer A. Doudna received a grant of 975 Deferred Share Units in Johnson & Johnson, bringing her total holding to 10,899 units. This was compensation, not an open-market purchase.
Director Daniel E. Pinto was awarded 1,712 Deferred Share Units in Johnson & Johnson, a compensation grant rather than a purchase, bringing his total holding to 2,174 units.
Johnson & Johnson director Mary C. Beckerle was awarded 975 Deferred Share Units on 2026-04-23, bringing her total holdings to 16,798 units.
Director Marillyn A. Hewson was awarded 975 Deferred Share Units on 2026-04-23 as compensation, bringing her total holding to 15,488 units.
Director John G. Morikis was awarded 1,540 Deferred Share Units at JNJ on 2026-04-23, a compensation grant rather than a market purchase. He now owns 1,540 units.
Director Paula A. Johnson was awarded 975 Deferred Share Units on 2026-04-23 as compensation, bringing her total holdings to 5,359 units. This was a grant, not an open-market purchase.
Johnson & Johnson director Hubert Joly was awarded 975 Deferred Share Units as compensation on 2026-04-23, bringing his total holdings to 9,184 units. This was a grant, not an open-market purchase.
Director Mark B. McClellan was awarded 975 Deferred Share Units in Johnson & Johnson on 2026-04-23 as compensation, bringing his total holding to 21,279 units.
Director Eugene A. Woods received a grant of 975 Deferred Share Units in Johnson & Johnson on 2026-04-23, bringing his total holdings to 6,215 units. This was compensation, not an open-market purchase.
Director Mark A. Weinberger received an award of 975 Deferred Share Units (compensation, not a purchase), bringing his total holding to 12,010 units.
Nadja West, a director at Johnson & Johnson, was awarded 975 Deferred Share Units as compensation on 2026-04-23, bringing her total holding to 7,730 units. This was a grant, not an open-market purchase.
Director Marillyn A. Hewson received two grants of Deferred Share Units totaling 282 units (206 and 75) as compensation, with no cash paid, bringing her holdings to 14,513 units.
Director Daniel E. Pinto was awarded 129 Deferred Share Units at Johnson & Johnson on 2026-03-10, a grant rather than a purchase, bringing his total holding to 462 units.
Transcripts
Earnings callsFY2026 Q32026-10-13
Earnings calls
AI summary
mixedJohnson & Johnson reported third quarter 2026 worldwide sales of $25.4 billion, up 6% operationally, with U.S. growth of 9.1% and 1.8% outside the U.S. Innovative Medicine sales were $16.8 billion, up 7.9% operationally, while MedTech sales were $8.6 billion, up 2.5% operationally. Net earnings were $210 million and diluted EPS was $0.09, impacted by the proposed talc litigation resolution and expenses of approximately $7 billion associated with the Firefly Bio transaction and Cell BioMedicines collaboration; adjusted net earnings were $6.3 billion and adjusted diluted EPS were $2.59, down 6.8% and 7.5% respectively. Management said the company is on track to exceed $100 billion in annual revenue for the first time and reiterated a clear path to double-digit growth by the end of the decade. MedTech results fell short of expectations, concentrated outside the U.S. and in Abiomed globally, and management said corrective actions are being taken.
Key takeaways
- Q3 operational sales growth of 6% came in ahead of analyst consensus, with sequential improvement versus Q2, according to management.
- Innovative Medicine delivered 7.9% operational growth with 8 brands growing double digits; oncology grew approximately 17% and Tremfya grew 68.2%.
- MedTech operational growth of 2.5% was below internal standards and prior investor expectations; pressure was concentrated outside the U.S. and in Abiomed globally, while U.S. MedTech growth accelerated to almost 5%.
- 29 products and platforms now generate at least $1 billion in annual sales, including CAPLYTA, which reached $1 billion in year-to-date sales.
- Management reaffirmed a path to double-digit growth by the end of the decade, driven by internal strategic investments rather than assumed inorganic additions.
Financial highlights
- Worldwide Q3 2026 sales were $25.4 billion, up 6% operationally, with U.S. growth of 9.1% and 1.8% outside the U.S.; acquisitions and divestitures had a net negative impact of 10 basis points.
- Innovative Medicine sales were $16.8 billion, up 7.9% operationally (U.S. +11.1%, ex-U.S. +3%); MedTech sales were $8.6 billion, up 2.5% operationally (U.S. +4.8%, ex-U.S. +0.1%).
- Q3 net earnings were $210 million and diluted EPS was $0.09 versus $2.12 a year ago; adjusted net earnings were $6.3 billion and adjusted diluted EPS were $2.59, down 6.8% and 7.5% respectively.
- Q3 free cash flow was more than $6 billion; the company ended the quarter with approximately $17 billion of cash and marketable securities, approximately $45 billion of debt, and a net debt position of approximately $28 billion.
Guidance
- Full-year 2026 operational sales growth is now expected in the range of 6.7% to 7.1%, representing operational sales of $100.7 billion at the midpoint, or growth of 6.9%; reported sales growth is estimated at 7.2% to 7.6%, with a midpoint of $101.2 billion, or 7.4%.
- Full-year 2026 adjusted operational EPS is expected in the range of $10.95 to $11.05, or 2% growth at the midpoint; reported adjusted EPS is expected in the range of $11.05 to $11.15, with a midpoint of $11.10, or 2.9% growth. Excluding the Firefly Bio and Cell BioMedicines transactions of $0.64, reported EPS growth would approach 9%.
- Full-year operating margin is now expected to decline approximately 60 basis points, an improvement from the 75-basis-point decline in July guidance; net interest expense guidance was lowered to $150 million to $200 million and the effective tax rate is now expected at 17.0% to 17.5%.
- For 2027 modeling, the company expects Firefly Bio and Cell BioMedicines to have a combined dilutive impact of $1.36 per share on full-year adjusted EPS; more details will be provided at the enterprise business review on December 8.
Q&A themes
- MedTech: analysts pressed on the below-expectation segment results, Abiomed's slowdown and corrective actions, and whether M&A is needed; management pointed to U.S. strength, ex-U.S. headwinds including VBP in China and Middle East disruption, and said the issues are not structural.
- ICOTYDE launch: discussion of psoriasis uptake (over 20,000 patients initiated and nearly 9,000 prescribers), payer access, patient sourcing (approximately 60% systemic naive, about 20% from orals and 20% from other treatments), and the opportunity in IBD and psoriatic arthritis.
- INLEXZO/Urology: analysts asked about the market opportunity; management cited year-to-date sales of approximately $200 million, with Q3 net sales north of $90 million and new patient starts up 45% versus the prior quarter, plus expansion potential into broader populations.
- Pipeline: questions covered the CARTITUDE V and VI trials in newly diagnosed multiple myeloma, earlier-line CARVYKTI use, and milvexian's factor XI program, including expected secondary stroke data this year and atrial fibrillation data next year.
Risks
- Q3 net earnings and diluted EPS were sharply lower year over year, primarily due to the proposed talc litigation resolution and approximately $7 billion of expenses tied to the Firefly Bio transaction and Cell BioMedicines collaboration.
- MedTech performance was below management's internal standards and prior expectations, concentrated in ex-U.S. markets and Abiomed globally; management cited competitive PFA pressure, VBP expansion in China, surgery transformation program impacts, and Middle East disruption affecting tender timing and ordering patterns.
- The ovarian talc litigation resolution of $5.5 billion is conditioned upon the express participation of at least 95% of claimants.
FY2026 Q22026-07-15
Earnings calls
AI summary
positiveJohnson & Johnson reported second quarter 2026 operational sales growth of 5.6% to $25.3 billion, beating expectations with adjusted diluted EPS of $2.90, up 4.7% year-over-year. Excluding STELARA headwinds of 460 basis points, the company grew double digits in the quarter. On the strength of Q2 performance and accelerating new product launches including ICOTYDE, INLEXZO, and RYBREVANT, management raised full-year 2026 operational sales growth guidance to 6.5%-7.1% (midpoint $100.6 billion) and adjusted operational EPS guidance to $11.50-$11.65, representing 7.3% year-over-year growth. Innovative Medicine delivered 6.8% operational growth despite STELARA declines, with eight brands achieving double-digit growth. MedTech grew 3.6% operationally, though cardiovascular faced headwinds from Abiomed procedure slowdown and China inventory dynamics. The company expects accelerated growth in the second half of 2026 and maintains confidence in reaching more than $100 billion in annual revenue for the first time in its 140-year history, with line of sight to double-digit growth by decade's end.
Key takeaways
- Q2 operational sales of $25.3 billion grew 5.6%, with double-digit growth excluding STELARA; company on track to exceed $100 billion annual revenue target for first time
- Innovative Medicine operational sales grew 6.8% to $16.4 billion with eight brands in double-digit growth; DARZALEX grew 17.6% to over $4 billion; TREMFYA delivered 71% growth driven by IBD launch momentum
- ICOTYDE launch significantly exceeding expectations with 11,000 patients initiated, 6,000 unique prescribers, and 50% commercial payer coverage within 90 days; INLEXZO achieving 1 in 3 eligible patient uptake with 75% quarter-over-quarter new patient insertion growth
- Company raised 2026 guidance on strong execution: operational sales growth now 6.5%-7.1% (midpoint $100.6 billion) and adjusted operational EPS $11.50-$11.65; second-half performance expected to improve
- Multiple pipeline catalysts expected in second half including IMAAVY FDA approval for warm autoimmune hemolytic anemia, TECVAYLI combination data, OTTAVA robotic surgery system FDA approval, and VARIPULSE Pro U.S. approval
Financial highlights
- Q2 2026 worldwide sales $25.3 billion, operational growth 5.6%; adjusted diluted EPS $2.90, up 4.7% year-over-year
- Innovative Medicine sales $16.4 billion, operational growth 6.8%; MedTech sales $8.9 billion, operational growth 3.6%
- Full-year 2026 operational sales growth guidance raised to 6.5%-7.1% with midpoint of $100.6 billion; adjusted operational EPS guidance $11.50-$11.65
- Adjusted pre-tax operating margin expected to improve approximately 75 basis points for full year; effective tax rate expected 17.0%-18.0%
Guidance
- Full-year 2026 operational sales growth guidance of 6.5%-7.1% with midpoint of $100.6 billion; reported sales growth 7.0%-7.6% with midpoint $101.1 billion including currency impacts
- Adjusted operational EPS guidance $11.50-$11.65, representing 7.3% year-over-year growth; reported EPS $11.60-$11.75
- Expects net interest expense of $250-$300 million and effective tax rate of 17.0%-18.0% for full year 2026
- Company on track for mid-2027 DePuy Synthes business separation; multiple regulatory and commercial catalysts expected in second half including OTTAVA FDA approval, IMAAVY FDA approval, and VARIPULSE Pro U.S. approval
Q&A themes
- ICOTYDE launch momentum with 11,000 patients initiated and 6,000 unique prescribers; co-positioning strategy with TREMFYA emphasizing distinct market positions as first-choice systemic and first-choice biologic respectively
- INLEXZO bladder cancer uptake accelerating with 1 in 3 eligible patients receiving treatment; SunRISe program expansion from BCG-unresponsive to BCG-experienced papillary and BCG-naive populations
- Abiomed procedure softness attributed to physician caution following neutral U.K. clinical trial on high-risk PCI; management actively engaging physicians and expects recovery in second half with PROTECT IV data in 2027
- TREMFYA achieving market leadership in IBD induction with 58% share in ulcerative colitis and over 50% in Crohn's disease; new FUSION data showing efficacy in perianal fistulizing Crohn's disease
Risks
- Abiomed business experiencing near-term procedure volume pressure due to physician selectivity following neutral clinical trial data; though management characterizes as temporary, recovery dependent on future clinical evidence and PROTECT IV study results in 2027
- MedTech cardiovascular growth significantly impacted by China inventory dynamics estimated at 400 basis points headwind and competitive pressures in electrophysiology; growth rates lower than recent trends
- STELARA declining 55.7% due to biosimilar competition and adoption of novel classes, creating significant revenue headwind; dependence on newer launches ICOTYDE and INLEXZO for sustained growth momentum in immunology segment
FY2026 Q12026-04-14
Earnings calls
AI summary
positiveJ&J delivered Q1 2026 operational sales of $24.1 billion with 6.4% growth, exceeding consensus and prompting raised guidance. Innovative Medicine grew 7.4% with strong performances from DARZALEX, TREMFYA, and newly launched ICOTYDE, while MedTech grew 4.6% across cardiovascular, surgery, and vision. The company remains on track to reach $100 billion in annual revenue for the first time and maintains confidence in double-digit growth by decade's end.
Key takeaways
- Q1 2026 operational sales growth of 6.4% ($24.1B); excluding STELARA headwind, growth was double-digit
- Innovative Medicine drove 7.4% growth with 10 brands in double-digit growth; DARZALEX sales $4B with 18% growth; TREMFYA grew 64%
- ICOTYDE launched with 1,500 prescriptions and 1,000+ unique customers within weeks; positioned as first-line systemic therapy for psoriasis alongside TREMFYA
- MedTech grew 4.6% with strength in electrophysiology (9.5%), Abiomed (14.4%), and Shockwave (18.1%); VARIPULSE and TECNIS PureSee FDA approved
- Full-year 2026 guidance raised: operational sales growth 5.9%-6.9% ($100.2B midpoint); adjusted EPS guidance increased $0.02 to $11.30-$11.50 range
Financial highlights
- Q1 2026 worldwide sales $24.1 billion, operational growth 6.4%
- Innovative Medicine sales $15.4 billion, operational growth 7.4%; MedTech sales $8.6 billion, operational growth 4.6%
- Adjusted diluted EPS $2.70 vs. $2.77 prior year; GAAP diluted EPS $2.14
- Free cash flow Q1 approximately $1.5 billion; full-year outlook $21 billion; net debt approximately $33 billion
Guidance
- Full-year 2026 operational sales growth guidance: 5.9%-6.9% with midpoint of $100.2 billion; reported growth 6.5%-7.5% reflecting 53rd week benefit
- Adjusted operational EPS guidance raised to $11.30-$11.50 range (5.7% growth at midpoint); reported EPS $11.55 at midpoint
- Adjusted pretax operating margin expected to improve by at least 50 basis points in 2026
- Free cash flow outlook maintained at approximately $21 billion for full year 2026
Q&A themes
- ICOTYDE positioning: first-line systemic therapy for psoriasis; ICONIC-ASCEND head-to-head trial with TYK2 inhibitor demonstrates differentiation; 1,500 early prescriptions with 50-90% increases in weekly new patient insertions post-J-code in April
- MedTech growth trajectory: focus on mid-to-high single-digit growth toward decade-end through OTTAVA robotic surgery, next-generation PFA catheters, Impella ECP, and orthopedics separation; Abiomed showed 16.3% absolute mortality reduction at 10 years vs. standard care
- INLEXZO (bladder cancer) outperforming recent launches; 1 in 5 eligible patients starting treatment in Q1; 50-90% increase in insertions following J-code approval in April; IRDA intravascular drug-releasing system in pipeline with 90%+ response rates
- JNJ-4804 coantibody (IL-23 + TNF inhibitor) for IBD: Phase II data in Crohn's and colitis to be presented this year; Phase III programs underway; addresses unmet need with 50%+ of patients not achieving remission on monotherapy
Risks
- STELARA headwind of approximately 540 basis points on overall sales growth and 920 basis points on Innovative Medicine due to biosimilar competition
- Adjusted segment margins declined: Innovative Medicine from 42.5% to 39.7% and MedTech from 25.9% to 22.3%, driven by new launch investments, tariffs, and unfavorable product mix
- MedTech faces competitive pressures in electrophysiology with new entrants; second-half 2026 impact from volume-based procurement in China for electrophysiology products already factored into guidance
FY2025 Q42026-01-21
Earnings calls
AI summary
positiveJ&J delivered 5.3% operational sales growth in 2025 despite ~620 basis points STELARA headwind, with Innovative Medicine growing 5.3% and Pharmaceutical sales exceeding $60B for the first time. The company guided 2026 operational sales growth of 5.7%-6.7% (~$100B midpoint), with confidence in reaching double-digit growth by late decade fueled by 28 billion-dollar brands and significant pipeline momentum across oncology, immunology, and neuroscience.
Key takeaways
- Pharmaceutical business exceeded $60B for first time with 13 brands growing double-digits; Oncology grew 21% operationally with $50B target by 2030
- TREMFYA reached $5B+ in global sales with 65% growth; DARZALEX grew 22% to $14B+; SPRAVATO grew 57% and CAPLYTA launched for adjunctive depression treatment
- MedTech grew 5.4% operationally to $34B; Cardiovascular delivered 15% operational growth with Abiomed and Shockwave growing ~18% and 23% respectively
- Company secured 51 approvals, filed 32 submissions, and delivered 17 positive key study readouts in 2025; invested $32B in R&D and M&A including Intra-Cellular Therapies and Halda Therapeutics acquisitions
Financial highlights
- Full year 2025: $94.2B sales (+5.3% operational); Q4 2025: $24.6B sales (+7.1%); adjusted diluted EPS $10.79 (+8.1%)
- Free cash flow $19.7B in 2025, with 2026 expected at ~$21B; ending 2025 with $20B cash and $48B debt ($28B net debt)
- Adjusted pretax operating margin improved to 28.7% in Q4 2025 from 24.1% in Q4 2024; Innovative Medicine margin improved to 36.3% from 32.5%
- Q4 2025 adjusted diluted EPS $2.46 (+20.6% vs Q4 2024); full year adjusted net earnings $26.2B
Guidance
- 2026 operational sales growth 5.7%-6.7% (midpoint $100B/6.2%); reported growth 6.2%-7.2% (midpoint $100.5B) including 100 basis point benefit from 53rd week
- 2026 adjusted operational EPS growth 5.5% midpoint ($11.28-$11.48 range); reported adjusted EPS $11.53 midpoint including ~$0.15 FX benefit
- Adjusted pretax operating margin improvement of at least 50 basis points in 2026; expects $500M full-year MedTech tariff impact and net interest expense $300-400M
- Effective tax rate 17.5%-18.5% in 2026; anticipate ICOTYDE approval in psoriasis, TECVAYLI approval in relapsed/refractory multiple myeloma, and OTTAVA robotic system submission in 2026
Q&A themes
- Multiple myeloma franchise positioning: TECVAYLI plus DARZALEX combination shows 83% reduction in progression/death risk in second line; TECVAYLI monotherapy reduces progression risk 71% in CD38-refractory patients; CARVYKTI CAR-T has treated 10,000+ patients with potential cure positioning
- EP business acceleration with 9.5% Q4 growth approaching double-digit U.S. growth; VARIPULSE now used in 40,000+ patients with commitment to launch new catheter annually and CARTO system updates twice yearly
- INLEXZO bladder cancer launch showing robust interest with permanent J-code expected Q2 2026; TAR-210 erdafitinib device platform expected with 90%+ complete response rates targeting intermediate-risk patients
- Talc litigation: Special master's Daubert report recommendation excludes certain plaintiff experts but J&J will appeal parts failing to apply proper gatekeeping; company will continue aggressive litigation strategy of fighting all meritless claims
Risks
- STELARA biosimilar competition and erosion continuing to accelerate (620 basis points 2025 headwind); Part D redesign impacting certain franchises
- MedTech tariffs estimated at $500M for full year 2026, significantly above 2025 levels; EP business facing competitive pressures in pulsed-field ablation market
- Talc litigation ongoing with uncertain appeal outcomes on Daubert ruling; novel regulatory pathway for OTTAVA robotic system with no predicate device requires successful de novo approval
FY2025 Q32025-10-14
Earnings calls
AI summary
positiveJ&J delivered Q3 2025 operational sales growth of 5.4% to $24 billion, with Innovative Medicine sales exceeding $15 billion for a second consecutive quarter and MedTech accelerating to 5.6% growth. The company announced a planned separation of its Orthopaedics business (DePuy Synthes) within 18-24 months to sharpen focus on six priority areas: oncology, immunology, neuroscience, cardiovascular, surgery, and vision.
Key takeaways
- Innovative Medicine grew 5.3% operationally despite ~1070 basis point STELARA headwind; 11 brands achieved double-digit growth including DARZALEX (+20%), TREMFYA (+40%), and CARVICTI (+81%)
- MedTech accelerated to 5.6% operational growth with cardiovascular (+12%), electrophysiology (+9.7%), Abiomed (+15.6%), and Shockwave (+20.9%) leading performance
- Announced planned separation of Orthopaedics business (DePuy Synthes) expected to complete within 18-24 months; separation expected to improve remaining MedTech top-line growth and margins by at least 75 basis points
- Raised 2025 full-year operational sales guidance to 4.8%-5.3% growth range (midpoint $93.2B) and reaffirmed adjusted EPS guidance of $10.85 with range $10.8-$10.9
Financial highlights
- Q3 2025 worldwide sales: $24 billion, +5.4% operational growth
- Innovative Medicine sales: $15 billion, +5.3% operational growth; Oncology grew ~20%, Immunology achieved 40% TREMFYA growth
- MedTech sales: $8.4 billion, +5.6% operational growth; Cardiovascular +12%, Electrophysiology +9.7%, Shockwave +20.9%
- Adjusted diluted EPS: $2.8, +15.7% versus prior year; Net earnings: $5.2 billion with diluted EPS of $2.12
Guidance
- 2025 full-year operational sales growth guidance: 4.8% to 5.3% (midpoint 5.1% or $93.2B), increased by ~$300M
- 2025 adjusted EPS guidance reaffirmed: $10.85 with range $10.8-$10.9 (8.7% midpoint growth)
- 2026 preliminary outlook: anticipate Innovative Medicine accelerated growth driven by TREMFYA in IBD, Ribrovan plus Lascluse in lung cancer, and Inlexo in bladder cancer; expect MedTech accelerated growth and Shockwave C2 Aero launch
- 2026 preliminary consensus commentary: current revenue consensus of 4.6% growth appears lower than J&J expects, which believes total will exceed 5%; adjusted EPS consensus of $11.39 may have upside of ~$0.05
Q&A themes
- Orthopaedics separation represents portfolio optimization to position J&J in higher-growth markets; separation expected to strengthen remaining MedTech business with focus on cardiovascular, surgery, and vision as core platforms
- Capital allocation priorities are R&D investment and portfolio funding over large M&A; company completed 60+ smaller deals in past 18 months (e.g., Inlexo acquired for couple hundred million, now projected $5B+ peak sales asset)
- Consensus appears to underestimate 2026 growth drivers, particularly TREMFYA (40% growth with 50% IL-23 share in ulcerative colitis pre-subcutaneous approval) and SPRAVATO (60.8% Q3 growth with 180K+ patients treated)
- Icotrokinra positioned as distinct $5B+ asset from TREMFYA with oral pill formulation and biologic-like efficacy; head-to-head studies versus STELARA support competitive positioning alongside continued TREMFYA growth
Risks
- STELARA loss of exclusivity continues to create significant headwind (~1070 basis points in Innovative Medicine, ~640 basis points company-wide) with biosimilar competition and Part D redesign impact ongoing
- Orthopaedics separation completion timeline of 18-24 months creates execution risk; separation represents transition period with potential for stranded costs and management attention diversion
- MedTech margin compression risk noted in Q3 (21% vs 24.1% prior year) driven by macroeconomic factors and cost of products sold, partially offset by expense leverage
FY2025 Q22025-07-16
Earnings calls
AI summary
positiveJ&J delivered Q2 2025 operational sales growth of 4.6% to $23.7 billion, with Innovative Medicine achieving over $15 billion in quarterly sales for the first time despite ~$1.2 billion STELARA erosion. The company raised full-year 2025 operational sales guidance by approximately $900 million to 4.5%-5.0% and increased adjusted EPS guidance by $0.25 to $10.85, driven by strong performance across oncology, immunology, neuroscience, and MedTech cardiovascular platforms.
Key takeaways
- Innovative Medicine grew 3.8% operationally with non-STELARA business growing 15.5%; 13 brands achieved double-digit growth including DARZALEX (21.5%), CARVYKTI (>100%), RYBREVANT plus LAZCLUZE (>100%), TREMFYA (30.1%), and SPRAVATO (53%)
- MedTech grew 6.1% operationally with Cardiovascular surging 22%, driven by Abiomed (16.9%), Shockwave double-digit growth, and electrophysiology (9.8%); VARIPULSE surpassed 10,000 cases globally with <0.5% neurovascular event rate
- Company targets #1 oncology position by 2030 with >$50 billion sales, with TAR-200 bladder cancer therapy expected to generate ≥$5 billion peak annual sales launching in H2 2025
- Pipeline catalysts expected in H2 2025 include TAR-200 approval, subcutaneous RYBREVANT, TREMFYA subcutaneous for ulcerative colitis, CAPLYTA for major depressive disorder, and icotrokinra filing in psoriasis
Financial highlights
- Q2 2025 worldwide sales: $23.7 billion, +4.6% operational growth; Innovative Medicine $15.2 billion (+3.8%); MedTech $8.5 billion (+6.1%)
- Adjusted diluted EPS: $2.77 (-1.8% vs Q2 2024); reported diluted EPS: $2.29 (+18.7% vs $1.93 prior year)
- Free cash flow through H1 2025: >$6 billion; net debt position: $32 billion ($19 billion cash, $51 billion debt)
- Full-year 2025 guidance raised: operational sales growth 4.5%-5.0% (midpoint $92.9 billion/4.8%); adjusted operational EPS $10.68 (7% growth); reported EPS $10.85 (range $10.80-$10.90)
Guidance
- Full-year 2025 reported sales growth: 5.1%-5.6% with midpoint of $93.4 billion (includes $1.1 billion incremental FX benefit vs prior guidance)
- Operating margin improvement of ~300 basis points expected for full year 2025; net interest expense guidance: $0-$100 million; effective tax rate: 17%-17.5%
- Both Innovative Medicine and MedTech expected to show higher operational sales growth in H2 2025 vs H1; STELARA biosimilar competition expected to accelerate with erosion similar to HUMIRA year 2
- Expected 2025 tariff impact reduced to ~$200 million (exclusively MedTech) from prior $400 million estimate
Q&A themes
- Oncology portfolio depth supports $50 billion 2030 target, with TAR-200 (≥$5 billion potential) and RYBREVANT plus LAZCLUZE ($5 billion+) as major delta drivers vs Street expectations
- RYBREVANT subcutaneous responded to manufacturing-related CRL questions; no additional clinical data required; approval expected H2 2025
- OTTAVA robotic surgery timeline on track: de novo FDA submission expected Q1 2026; first patient cases completed Q1 2025; strong physician feedback on differentiation vs competitors
- VARIPULSE pulsed field ablation showing strong adoption with 10,000+ global cases and competitive safety/efficacy profile; comprehensive next-generation PFA portfolio (Dual Energy STSF, OMNYPULSE) advancing in development
Risks
- STELARA biosimilar competition expected to accelerate throughout 2025 with erosion patterns similar to HUMIRA's second year; Part D redesign continues to impact reimbursement
- Tariff policy uncertainty remains; company currently does not include Most Favored Nation (MFN) impact in guidance; 2026 GILTI tax rate increase from 10.5% to 12.6% expected to add ~1% to global effective tax rate
- MedTech Surgery and Orthopedics remain underperformers despite new product initiatives; company targets 5-7% operational growth for orthopedics through 2027 but results not yet accelerating as planned
Company news
Reuters, WSJ, Bloomberg and FT first, as far as our news provider delivers them; other publishers behind the second filter. Headlines link to the publisher.- Johnson & Johnson to Buy Ollin Biosciences for $2.2 Billion
- J&J eyes US nod for Caplyta in bipolar mania after second trial win
- J&J's once-daily pill eases psoriatic arthritis symptoms in late-stage trial
- Smith+Nephew cuts outlook, confirms failed merger talks with J&J's orthopaedics unit
- Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial
- UK approves J&J's oral psoriasis pill
- Glucose monitoring devices for type 2 diabetes benefit even those not on insulin
- Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin
- J&J Is Leaning Toward Spinning Out Its Hips-And-Knees Business
- J&J's Caplyta meets main goal of bipolar mania study
Company data
Company intelligence
Updated: Nov 22, 2026, 11:57 AM UTC
Company data
Company intelligence
Company profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Chief executive
- Joaquin Duato
- Employees
- 141,700
- IPO date
- Jan 2, 1962
- Country
- US
- Exchange
- New York Stock Exchange
Rating factors
- Return on equityi
- 5/5
- Return on assetsi
- 5/5
- Debt to equityi
- 2/5
- Price to earningsi
- 1/5
- Price to booki
- 1/5
Company press releases
Congressional disclosures
Senate
House
Market cap history
Largest fund holders
| Fund | Weight | Shares held |
|---|---|---|
| VOO | 1.01% | 64M |
| VTI | 0.9% | 60.4M |
| IVV | 1.06% | 32.4M |
| 1657.T | 0.81% | 32.4M |
| XAW.TO | 0.63% | 32.4M |
| XUU.TO | 0.95% | 32.4M |
| SPY | 1.06% | 29.8M |
| FXAIX | 0.97% | 29.4M |
| VTV | 2.37% | 23.2M |
| XLV | 10% | 17.8M |
| VECA.S | 0.27% | 14.3M |
| VIG | 2.74% | 13.7M |
Analyst track record
How the analysts covering JNJ have done: ratings, price-target accuracy and the measured reaction after their calls.
| 12 months | 3 years | |
|---|---|---|
| Ratings | 173 | 489 |
| Analysts | 27 | 36 |
| Buy / hold / sell | 125 / 47 / 1 | 284 / 204 / 1 |
| Upgrades / downgrades / initiations | 2 / 2 / 1 | 8 / 5 / 5 |
| Price targets hit / missed | 77 / 86 (47%) | 365 / 86 (81%) |
| Avg. return after a rating (TipRanks) | +2.5% | +33.2% |
| Best / worst call | +142.9% / -16.5% | +142.9% / -16.5% |
After buy calls on this stock: median 21-day move +1.3% vs S&P 500 -1.1% (n = 305)
Most accurate on this stock
Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.
- Asad HaiderGoldman Sachs100% hit rate on this stock · 9 targets measuredBuytarget $280Oct 26, 2026
- Joanne WuenschCiti64% hit rate on this stock · 14 targets measuredBuytarget $303Oct 5, 2026
- Josh JenningsTD Cowen57% hit rate on this stock · 21 targets measuredBuytarget $250Apr 23, 2026
Latest ratings
| Date | Analyst | Call | Target | |
|---|---|---|---|---|
| Nov 20, 2026 | Chris SchottJ.P. MorganNov 20, 2026 | HoldReiterated | $300↗ | article ↗ |
| Nov 17, 2026 | Jason GerberryBank of America SecuritiesNov 17, 2026 | HoldMaintained | $292↗ | article ↗ |
| Nov 17, 2026 | David RisingerLeerink PartnersNov 17, 2026 | BuyMaintained | $272↗ | article ↗ |
| Nov 11, 2026 | Jason GerberryBank of America SecuritiesNov 11, 2026 | HoldReiterated | $275↗ | article ↗ |
| Nov 9, 2026 | Louise ChenScotiabankNov 9, 2026 | BuyMaintained | $305↗ | article ↗ |
Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.
TipRanks data · computed Nov 20, 2026 · 173 ratings
Frequently asked questions
Where can I trade JNJ perpetual futures?
Johnson & Johnson (JNJ) perpetual futures trade on 11 crypto venues, including LBank, Bybit, BingX. PerpEquities compares them by live price, funding rate, open interest and liquidity.
Can I trade JNJ around the clock?
Yes. Unlike the underlying stock, JNJ perpetuals trade 24/7 — including weekends and outside regular market hours.
What is the funding rate on JNJ perpetuals?
Right now the JNJ perp funding rate is 0.0% annualized (venue median), ranging from -2.6% to +11.0% across 11 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.
How does the JNJ perp price compare to the Johnson & Johnson stock?
The venue-median JNJ perp mark is $266.4 versus a reference stock price of $266.5, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.
What is a JNJ perpetual future?
A JNJ perpetual is a derivative that tracks the price of Johnson & Johnson with no expiry date. It lets you take long or short exposure to Johnson & Johnson on crypto venues, around the clock.
What is JNJUSDT perpetual?
JNJUSDT is the symbol most crypto exchanges use for the Johnson & Johnson perpetual settled in USDT (Tether). It tracks the JNJ share price through an index, trades 24/7 with leverage and never expires.
Bybit
BingX
Bitget
Binance
MEXC
XT.com
OKX
HTX
Bitunix
Gate.io
LBank